focus -WSS

focus

author：leisure time 2025-10-01 02:14:15 - browse：15

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： A daunting task: navigating dual Medicare, Medicaid eligibility

WSS

Anthos stroke drug appears safer than common blood thinner

TB outbreak tied to bone grafts underscores testing shortcomings

GOP presidential candidates start declaring their loyalty

White House drug shortages task force keeps mum with Congress

Why medical students are struggling with mental health

Why medical students are struggling with mental health

focus

focus

knowledge

How one medical school became remarkably diverse

PBM reforms clear House panel

How to save PrEP access — and even expand it

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Maui funeral service workers on devastation of fires: 'I'm in shock'

How one medical school became remarkably diverse

Anthos stroke drug appears safer than common blood thinner

In Memoriam: Notable people who died in 2023

Anthos stroke drug appears safer than common blood thinner

hotspot

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

PBM reforms clear House panel

Ransomware attacks on hospitals: Study outlines patient impact

Gain of function research would be limited under House proposal

Large hospital system sues Multiplan for low

Who are the detained American citizens released from prison in Iran?

knowledge

focus

focus

explore